Drug repositioning in neurodegeneration: An overview of the use of ambroxol in neurodegenerative diseases.


Journal

European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354

Informations de publication

Date de publication:
05 Oct 2020
Historique:
received: 14 04 2020
revised: 30 06 2020
accepted: 29 07 2020
pubmed: 3 8 2020
medline: 19 5 2021
entrez: 3 8 2020
Statut: ppublish

Résumé

Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease in adults. While it is primarily characterized by the death of upper and lower motor neurons, there is a significant metabolic component involved in the progression of the disease. Two-thirds of ALS patients have metabolic alterations that are associated with the severity of symptoms. In ALS, as in other neurodegenerative diseases, the metabolism of glycosphingolipids, a class of complex lipids, is strongly dysregulated. We therefore assume that this pathway constitutes an interesting avenue for therapeutic approaches. We have shown that the glucosylceramide degrading enzyme, glucocerebrosidase (GBA) 2 is abnormally increased in the spinal cord of the SOD1

Identifiants

pubmed: 32739173
pii: S0014-2999(20)30538-0
doi: 10.1016/j.ejphar.2020.173446
pii:
doi:

Substances chimiques

Enzyme Inhibitors 0
Neuroprotective Agents 0
Ambroxol 200168S0CL
Sod1 protein, mouse EC 1.15.1.1
Superoxide Dismutase-1 EC 1.15.1.1
beta-Glucosidase EC 3.2.1.21
beta-glucosidase 2, mouse EC 3.2.1.21
GBA2 protein, human EC 3.2.1.45
Glucosylceramidase EC 3.2.1.45

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

173446

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Auteurs

Alexandra Bouscary (A)

INSERM U1118, Mécanismes Centraux et Périphériques de la Neurodégénérescence, Université de Strasbourg, France; Université de Strasbourg, UMR-S 1118, Fédération de Médecine Translationnelle, Strasbourg, France.

Cyril Quessada (C)

INSERM U1118, Mécanismes Centraux et Périphériques de la Neurodégénérescence, Université de Strasbourg, France; Université de Strasbourg, UMR-S 1118, Fédération de Médecine Translationnelle, Strasbourg, France.

Frédérique René (F)

INSERM U1118, Mécanismes Centraux et Périphériques de la Neurodégénérescence, Université de Strasbourg, France; Université de Strasbourg, UMR-S 1118, Fédération de Médecine Translationnelle, Strasbourg, France.

Michael Spedding (M)

Spedding Research Solutions SAS, Le Vesinet, France.

Alexandre Henriques (A)

Neuro-sys SAS, Gardanne, France.

Shyuan Ngo (S)

Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia; Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia; Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.

Jean-Philippe Loeffler (JP)

INSERM U1118, Mécanismes Centraux et Périphériques de la Neurodégénérescence, Université de Strasbourg, France; Université de Strasbourg, UMR-S 1118, Fédération de Médecine Translationnelle, Strasbourg, France. Electronic address: loeffler@unistra.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH